1、January 2024By Darcy GrabensteinSenior Manager of Content StrategyArticleThe Pharmaceutical Industry:2024(and Beyond)Predictions2January 2024 Copyright 2024 Citeline,a Norstella company.(Unauthorized photocopying prohibited).The Pharmaceutical Industry:2024(and Beyond)PredictionsThis year we can exp

2、ect many recurring themes in the pharmaceutical industry,including decentralized clinical trials and a call for greater diversity.And,of course,no discussion of drug development or just about any industry,for that matter would be complete without mentioning artificial intelligence(AI).Lets review so

3、me of 2023s most prevalent trends in pharma and see where they are headed for 2024.Introduction3January 2024 Copyright 2024 Citeline,a Norstella company.(Unauthorized photocopying prohibited).The Pharmaceutical Industry:2024(and Beyond)PredictionsInitially spurred by necessity due to the coronavirus

4、 pandemic,DCTs have held their own.The acceptance and adoption of decentralized DCTs have become widespread,and sponsors are likely to continue employing them in the future.Decentralized Clinical Trials(DCTs)Source:Trialtrove,February 2023Both the European Medicines Agency(EMA)and the US Food and Dr

5、ug Administration(FDA)recognize the benefits of DCTs.In December 2022,the EMA issued recommendations on DCTs,addressing the roles and responsibilities of the sponsor and investigator,electronic informed consent,investigational medical product(IMP)delivery,trial-related procedures at home,data manage

6、ment,and monitoring.In May,the FDA issued a draft guidance on decentralized clinical trials(DCTs)aimed at supporting the use of such trials for drugs,biologics,and devices.The biggest issue for DCT stakeholders is change management,“this concept of were going to do things differently,”says Catherine